Table 2.

Summary of characteristics of vaccine against COVID-19 -related Miller-Fisher syndrome cases

References	Gender	Age (years)	History	Vaccination	Ophthalmoplegia	Ataxia	Areflexia	Sensory symptoms	Weakness	Other cranial nerve	Dysautonomia	Onset since vaccine, days	Serology	Miller Fisher diagnosis	CSF	Treatment	Outcome
Dang et al. [22]	M	63	Clear	ChAdOx1-SARS-COV-2	Υes	Υes	Yes	Υes	Υes	Facial	No	14	Negative	Probable	No cells, Increased protein (> 100 mg/dL)	IVIG	Improvement
Nishiguchi et al. [23]	M	71	Diabetes	BNT162b2 (1st dose)	Υes	Υes	No	No	No	–	No	18	Negative	Probable	No cells, Increased protein (< 100 mg/dL)	IVIG	Improvement
Yamakawa et al. [24]	M	30	Nothing reported	BNT162b2 (2nd dose)	Υes	Υes	Υes	No	No	–	No	7	Anti-GQ1b and anti-GT1a immunoglobulin G (IgG)	Definite	Normal	IVIG	Improvement
Michaelson et al. [25]	M	78	Clear	BNT162b2 (2nd dose)	Υes	Υes	Υes	Υes	No	–	No	13	Anti-GQ1b (equivocal)	Definite	No cells, Increased protein (> 100 mg/dL)	IVIG	Improvement
Abičić et al. [26]	F	28	Clear	BNT162b2 (1st dose)	Υes	No	No	No	No	–	No	18	Anti-GQ1b	Definite	Normal	IVIG	Improvement
Kim et al. [31]	F	84	Nothing reported	ChAdOx1-SARS-COV-2	Υes	Υes	Υes	No	No	–	No	8	Anti-GQ1b	Definite	NR	No	Improvement
Sansen et al. [29]	M	65	Diabetes	BNT162b2 (1st dose)	Υes	Υes	No	No	No	–	No	35	Anti-sulfatide	Probable	No cells, Increased protein (> 100 mg/dL)	IVIG	Improvement
Siddiqi et al. [28]	M	53	Hypertension	Sinovac	Υes	Υes	Υes	Υes	Υes	–	No	8	Not tested	Probable	No cells, Increased protein (> 100 mg/dL)	No	Improvement